{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T22:58:09Z","timestamp":1788044289062,"version":"build-2784847793"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"abstract":"<jats:p>\n                    Chronic kidney disease (CKD) is defined as an abnormality of the kidney's structure or function that is present for more than 3 months. Secondary hyperparathyroidism is a consequence of CKD, which eventuates with a decrease in the glomerular filtration rate. This study aimed to evaluate the effectiveness of alternate-day cinacalcet in noncompliant dialysis patients compared with a daily dose. The effects on the levels of intact parathyroid hormone (iPTH), calcium, and phosphorus were measured, and the compliance of patients with our protocol was observed. We followed the patients\u2019 (\n                    <jats:italic toggle=\"yes\">n<\/jats:italic>\n                    = 134) iPTH levels every 3 months and their serum calcium and phosphorous monthly for 6 months and compared the results with 6 months of data from patients receiving daily doses of cinacalcet. The patients\u2019 mean age was 49.54 \u00b1 16.17 years, the mean duration of dialysis was 6.44 \u00b1 5.10 years, and 37.3% had diabetic nephropathy. The mean dose of alternate-day cinacalcet was 61.92 \u00b1 26.59 mg. The level of iPTH before and after the change was 924.63 \u00b1 474.132 pg\/mL and 787.87 \u00b1 496.49 pg\/mL, respectively (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.001), and the mean serum calcium level before and after was 8.56 \u00b1 1.91 mg\/dL and 8.85 \u00b1 1.25 mg\/dL, respectively (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.035). The level of serum phosphorous before and after the change was 4.81 \u00b1 1.32 mg\/dL and 5.08 \u00b1 2.3 mg\/dL, respectively (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.204). Cinacalcet produced significant reductions in iPTH with intermittent (three times per week) doses and thus was more cost-effective and had better compliance.\n                  <\/jats:p>","DOI":"10.4103\/1319-2442.388184","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T02:36:45Z","timestamp":1697683005000},"page":"503-508","source":"Crossref","is-referenced-by-count":3,"title":["The Effectiveness of Alternate-day Cinacalcet Therapy for Secondary Hyperparathyroidism in Noncompliant Hemodialysis Patients"],"prefix":"10.4103","volume":"33","author":[{"given":"Mohammed","family":"Al-Homrany","sequence":"first","affiliation":[{"name":"Diaverum Renal Care, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Saeed","sequence":"additional","affiliation":[{"name":"Diaverum Renal Care, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furqan","family":"Ali","sequence":"additional","affiliation":[{"name":"Diaverum Renal Care, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Al-Ghamdi","sequence":"additional","affiliation":[{"name":"Diaverum Renal Care, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dujanah","family":"Mousa","sequence":"additional","affiliation":[{"name":"Diaverum Renal Care, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alharbi","family":"Ali","sequence":"additional","affiliation":[{"name":"Diaverum Renal Care, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,10,19]]},"reference":[{"key":"R1-20231021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","article-title":"KIDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","volume":"7","year":"2017","journal-title":"Kidney Int Suppl"},{"key":"R2-20231021","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2215\/CJN.06040710","article-title":"Secondary hyperparathyroidism: Pathogenesis, disease progression, and therapeutic options","volume":"6","author":"Cunningham","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"R3-20231021","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/ki.2008.264","article-title":"Chronic kidney disease and bone fracture: A growing concern","volume":"74","author":"Nickolas","year":"2008","journal-title":"Kidney Int"},{"key":"R4-20231021","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s00467-009-1337-0","article-title":"Cardiovascular risk in chronic kidney disease (CKD): The CKD-mineral bone disorder (CKD-MBD)","volume":"25","author":"Hruska","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"R5-20231021","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J Clin Invest"},{"key":"R7-20231021","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1385\/ENDO:10:2:97","article-title":"The calcimimetic NPS R-568 decreases plasma PTH in rats with mild and severe renal or dietary secondary hyperparathyroidism","volume":"10","author":"Fox","year":"1999","journal-title":"Endocrine"},{"key":"R8-20231021","first-page":"473","article-title":"NPS R-568: A type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium","volume":"290","author":"Fox","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"R10-20231021","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1681\/ASN.V1341017","article-title":"The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism","volume":"13","author":"Goodman","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"R11-20231021","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.ajkd.2006.01.015","article-title":"Meta-analysis of biochemical and patient-level effects of calcimimetic therapy","volume":"47","author":"Strippoli","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"R12-20231021","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1161\/CIRCULATIONAHA.114.013876","article-title":"Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: The evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial","volume":"132","author":"Moe","year":"2015","journal-title":"Circulation"},{"key":"R13-20231021","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/ndt\/gfq725","article-title":"The ADVANCE study: A randomized study to evaluate the effects of cinacalcet plus low-dose Vitamin D on vascular calcification in patients on hemodialysis","volume":"26","author":"Raggi","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"R14-20231021","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/ki.2010.167","article-title":"Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients","volume":"78","author":"Block","year":"2010","journal-title":"Kidney Int"},{"key":"R15-20231021","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2215\/CJN.03591006","article-title":"The OPTIMA study: Assessing a new cinacalcet (Sensipar\/Mimpara) treatment algorithm for secondary hyperparathyroidism","volume":"3","author":"Messa","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"R16-20231021","first-page":"229","article-title":"Intermittent dosing of cinacalcet is also effective in treating secondary hyperparathyroidism in hemodialysis patients","volume":"4","author":"Al-Hwiesh","year":"2013","journal-title":"Pharmaceutica Anal Acta"},{"key":"R17-20231021","first-page":"448","article-title":"A novel dose regimen of cinacalcet in the treatment of severe hyperparathyroidism in hemodialysis patients","volume":"22","author":"Al-Hilali","year":"2011","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"R18-20231021","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2147\/IJNRD.S124844","article-title":"Efficacy of low-dose cinacalcet on alternate days for the treatment of secondary hyperparathyroidism in hemodialysis patients: A single-center study","volume":"10","author":"Gojaseni","year":"2017","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"R19-20231021","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1345\/aph.1D108","article-title":"Calcimimetics and the treatment of primary and secondary hyperparathyroidism","volume":"38","author":"Joy","year":"2004","journal-title":"Ann Pharmacother"},{"key":"R20-20231021","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block","year":"2004","journal-title":"N Engl J Med"},{"key":"R21-20231021","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1210\/jc.2012-4003","article-title":"Pharmacodynamics of cinacalcet over 48 hours in patients with controlled secondary hyperparathyroidism: Useful data in clinical practice","volume":"98","author":"Arenas","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"R22-20231021","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2215\/CJN.07730814","article-title":"The effects of cinacalcet in older and younger patients on hemodialysis: The evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial","volume":"10","author":"Parfrey","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"R23-20231021","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1681\/ASN.2014040414","article-title":"Effects of cinacalcet on fracture events in patients receiving hemodialysis: The EVOLVE trial","volume":"26","author":"Moe","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"R24-20231021","doi-asserted-by":"crossref","first-page":"e1001436","DOI":"10.1371\/journal.pmed.1001436","article-title":"Cinacalcet in patients with chronic kidney disease: A cumulative meta-analysis of randomized controlled trials","volume":"10","author":"Palmer","year":"2013","journal-title":"PLoS Med"}],"container-title":["Saudi Journal of Kidney Diseases and Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/1319-2442.388184","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:14:19Z","timestamp":1787166859000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/1319-2442.388184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/1319-2442.388184","relation":{},"ISSN":["1319-2442","2320-3838"],"issn-type":[{"value":"1319-2442","type":"print"},{"value":"2320-3838","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]}}}